See more : eCargo Holdings Limited (ECG.AX) Income Statement Analysis – Financial Results
Complete financial analysis of Evelo Biosciences, Inc. (EVLO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Evelo Biosciences, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- The North West Company Inc. (NWC.TO) Income Statement Analysis – Financial Results
- Nurosene Health Inc. (MNNDF) Income Statement Analysis – Financial Results
- Thai-German Products Public Company Limited (TGPRO.BK) Income Statement Analysis – Financial Results
- ANYCOLOR Inc. (5032.T) Income Statement Analysis – Financial Results
- Nanfang Black Sesame Group Co., Ltd. (000716.SZ) Income Statement Analysis – Financial Results
Evelo Biosciences, Inc. (EVLO)
About Evelo Biosciences, Inc.
Evelo Biosciences, Inc., a biotechnology company, discovers and develops oral biologics for the treatment of inflammatory diseases and cancer. It is developing EDP1815, a whole-microbe candidate for the treatment of inflammatory diseases; and is in Phase 2 clinical trial for the treatment of psoriasis and atopic dermatitis, as well as for the hyperinflammatory response associated with COVID-19. The company also develops EDP1867, an inactivated investigational oral biologic, which is in Phase 1b for the treatment of inflammatory diseases; EDP2939, an extracellular vesicle investigational oral biologic for the treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 78.55M | 83.64M | 69.62M | 63.13M | 39.89M | 19.96M | 9.13M |
| General & Administrative | 29.91M | 31.75M | 22.27M | 23.23M | 18.22M | 7.57M | 3.89M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 29.91M | 31.75M | 22.27M | 23.23M | 18.22M | 7.57M | 3.89M |
| Other Expenses | 0.00 | 486.00K | -1.37M | 1.08M | 1.16M | -301.00K | -20.00K |
| Operating Expenses | 108.47M | 115.40M | 91.89M | 86.36M | 58.10M | 27.53M | 13.03M |
| Cost & Expenses | 108.47M | 115.40M | 91.89M | 86.36M | 58.10M | 27.53M | 13.03M |
| Interest Income | 4.67K | 3.61K | 0.00 | 1.05K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 4.67M | 3.61M | 2.11M | 1.05M | 1.56M | 0.00 | 0.00 |
| Depreciation & Amortization | 2.06M | 2.22M | 2.03M | 1.76K | 1.94K | 834.00 | 495.00 |
| EBITDA | -106.35M | -115.40M | -91.89M | -86.36M | -58.10M | -26.70M | -12.53M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -108.47M | -115.40M | -91.89M | -86.36M | -58.10M | -27.53M | -13.03M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -5.13M | -6.35M | -1.37M | 885.00K | 1.16M | -516.00K | -307.00K |
| Income Before Tax | -113.60M | -121.75M | -93.26M | -85.47M | -56.95M | -28.05M | -13.33M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 930.00K | 428.00K | 409.00K | 190.00K | -3.09M | 215.00K | 287.00K |
| Net Income | -114.53M | -122.18M | -93.67M | -85.66M | -53.85M | -28.05M | -13.33M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -26.28 | -46.18 | -47.45 | -53.49 | -49.25 | -149.98 | -94.55 |
| EPS Diluted | -26.28 | -46.18 | -47.45 | -53.49 | -49.25 | -149.55 | -94.06 |
| Weighted Avg Shares Out | 4.36M | 2.65M | 1.97M | 1.60M | 1.09M | 187.00K | 141.00K |
| Weighted Avg Shares Out (Dil) | 4.36M | 2.65M | 1.97M | 1.60M | 1.09M | 187.54K | 141.74K |
Evelo Biosciences to Report Second Quarter 2021 Financial Results on Thursday, July 29, 2021
CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that it will host a conference call and live webcast at 8:30 a.m. ET...
Evelo Biosciences Announces Grant of Inducement Award
CAMBRIDGE, Mass., July 14, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced that on July 12, 2021, Ayse Kocak commenced her services as Evelo's Head...
Evelo Biosciences Announces Grant of Inducement Award
CAMBRIDGE, Mass., June 16, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced that on June 14, 2021, Mark Plinio commenced his services as Evelo's Chief...
Evelo Biosciences Announces Inducement Award Plan for Expanding Leadership Team
CAMBRIDGE, Mass., June 03, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq: EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, announced that given accelerating growth to later-stage development and the anticipated hiring and expansion...
Evelo Biosciences: Monoclonal Microbes Offer Novel Inflammatory Treatment With A Favorable Risk-Reward Profile
Evelo Biosciences, Inc. is a clinical-stage biotechnology company developing novel oral biologics intended to act on cells in the small intestine for immunomodulatory effects. Evelo's pipeline consists of four announced therapeutics (2 clinical-stage) across 4 indications (COVID-19, psoriasis, atopic dermatitis,...
Evelo Biosciences, Inc (EVLO) CEO Simba Gill on Q1 2021 Results - Earnings Call Transcript
Evelo Biosciences, Inc (EVLO) CEO Simba Gill on Q1 2021 Results - Earnings Call Transcript
Evelo Biosciences to Present at 20th Annual Needham Virtual Healthcare Conference
CAMBRIDGE, Mass., April 05, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that management will present a company overview at the 20th Annual Needham Virtual Healthcare...
Evelo Biosciences & Abdul Latif Jameel Health Announce Strategic Collaboration to Develop & Commercialize Novel Therapy EDP1815 for Inflammatory Diseases & COVID-19 in Select Developing Markets Serving 1.7 Billion People
-- Collaboration expected to accelerate access to Evelo's lead inflammation product candidate and COVID-19 therapeutic medicine EDP1815 - if approved by relevant health authorities - to people in select developing markets and is Abdul Latif Jameel Health's first biotechnology licensing...
Evelo Biosciences, Inc. (EVLO) CEO Balkrishan Gill on Q4 2020 Results - Earnings Call Transcript
Evelo Biosciences, Inc. (EVLO) CEO Balkrishan Gill on Q4 2020 Results - Earnings Call Transcript
Evelo Biosciences Announces Fourth Quarter and Full Year 2020 Financial Results and Business Highlights
–Announced new positive data in human experimental model of inflammation of EDP1815––Completed enrollment in Phase 2b dose-ranging trial for EDP1815 in psoriasis; full data set accelerated and now expected in 3Q 2021––Initiated Phase 1b clinical trial of EDP1867 in atopic...
Source: https://incomestatements.info
Category: Stock Reports